Company intelligence / Profile preview

Theragnostic

London, UK

Ownership: Private
Development stage: Other

Overview

Developed radio-labelled PARP inhibitors for tumor diagnosis and treatment; assets acquired by Ariceum Therapeutics in June 2023, including Auger-based PARP inhibitor therapies and NEPHROSCAN diagnostic product.[2]

Therapeutic areas: Oncology
Modalities: Radiopharmaceutical
Industry: Biotech

Partnerships

GE Healthcare (NEPHROSCAN)Novartis (Ga-68 kit IP)

Beyond the preview

Go deeper on Theragnostic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theragnostic.

Explore the full profile